


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中生北控生物科技股份有限公司**  
**BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION**

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 8247)**

**FURTHER ANNOUNCEMENT**  
**PAST CONTINUING CONNECTED TRANSACTIONS**

Reference is made to the announcement of Biosino Bio-Technology and Science Incorporation (the “**Company**”) dated 9 May 2024 (the “**Announcement**”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Announcement.

The Company would like to provide additional information on (i) the remedial actions and (ii) the pricing terms and policies.

**I. THE REMEDIAL ACTIONS**

Save as disclosed in the Announcement, the following remedial actions have also been taken by the Company to ensure the strict compliance by the Company with the GEM Listing Rules in the future:

1. to increase the frequency of updating the list of connected persons by reviewing the list on a quarterly basis; and
2. to strengthen the identification process of connected persons, in particular for new clients or existing clients with larger transaction amount (i.e. over RMB2,000,000).

The Board hereby announces that, as at the date of this announcement, all of the remedial actions have been implemented. The audit committee of the Company and the Board will continue to closely monitor the ongoing internal control system of the Group to ensure it has in place adequate internal controls and procedures to meet its obligations under the GEM Listing Rules.

## II. THE PRICING TERMS AND POLICIES

### Purchases

As disclosed in the Announcement, in order to ensure that the prices were fair and reasonable and in line with prevailing market rates, the Group obtained quotations of the products and materials which are of similar nature, quantity and delivery time frame from not fewer than two independent third parties, at a frequency not less than on a quarterly basis.

Such quotations were reviewed and evaluated from the commercial perspectives by the procurement manager of the relevant subsidiary and compared against the quotation from Anhui Guoke. The comparison results were then reported by the procurement manager of the subsidiary to a former vice president of the Company, who was also responsible for the management of the subsidiary. The Group only accepted Anhui Guoke's quotation when the prices and terms offered by Anhui Guoke were no less favourable than those offered to the Group by the independent third parties.

As the transactions were conducted in accordance with the pricing principles as disclosed above, the transactions enabled the Group to purchase products and materials required for its operations at a reasonable and competitive price, which was on normal commercial terms and consistent with the prevailing market price.

### Sales

As disclosed in the Announcement, the prices and terms of the Products sold to the Anhui Guoke were not more favourable than those offered to independent third parties.

The selling prices for products which are of similar nature and quality provided by the Group to the independent third parties were taken into account for reference, relying on the sales agreements entered into between the Group and the independent third parties within the past three months at that time. Prior to sales to Anhui Guoke, the sales manager of the relevant subsidiary was responsible to review the prices and terms of the Products sold to Anhui Guoke, to ensure the prices and terms were no more favourable than those offered by the Group to independent third parties.

As the transactions were conducted in accordance with the pricing principles as disclosed above, the transactions enable the Group to sell products on normal commercial terms and in consistent with the prevailing market prices.

Save as stated above, all other information set out in the Announcement remains unchanged.

For and on behalf of the Board  
**Biosino Bio-Technology and Science Incorporation**  
**Wu Lebin**  
*Chairman and Executive Director*

Beijing, the PRC, 27 May 2024

As at the date of this announcement, the Board comprises:

*Chairman and executive Director*

Mr. Wu Lebin (吳樂斌先生)

*Vice chairmen and non-executive Directors*

Mr. Yang Peng (楊鵬先生) and Mr. Chen Zhengyong (陳正永先生)

*President and executive Director*

Mr. Chen Peng (陳鵬先生)

*Non-executive Directors*

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

*Independent non-executive Directors*

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangan (沈劍剛教授)

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its posting and on the website of the Company at [www.zhongsheng.com.cn](http://www.zhongsheng.com.cn).*